Prevnar

Type: Product
Name: Prevnar
First reported 3 hours ago - Updated 1 hour ago - 3 reports

Booster Shots: Pfizer Acquiring Two Baxter Vaccines for $635M

Pfizer agreed to acquire Baxter International’s two vaccines commercially marketed outside the U.S., and a related production facility for $635 million, the companies said today, as the seller prepares to spin out its biopharma business as part of a plan ... [Published Genetic Engineering News - 1 hour ago]
First reported 10 hours ago - Updated 10 hours ago - 1 reports

Pfizer profit falls 79 percent in Q2

(MENAFN) Earnings of Pfizer dropped 79 percent in the second quarter compared to last year, when the world"s second-largest drugmaker booked ... [Published MENAFN - 10 hours ago]
First reported Jul 29 2014 - Updated 19 hours ago - 3 reports

Earnings at Pfizer tank but still just beat expectations

Taking the brunt of generic competition to former blockbuster drugs, US pharma giant Pfizer (NYSE: PFE) posted a massive 79.4% drop in second-quarter 2014 earnings.Earnings plunged to $2.91 billion, or $0.45 per share, minus 77.3%, compared with $14.1 ... [Published Pharma Letter - Jul 29 2014]
Entities: Pfizer Inc, Prevnar, Enbrel
First reported Jul 29 2014 - Updated Jul 29 2014 - 2 reports

Pfizer's profit sinks

New York - Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a business spinoff gain of more than $10 billion (R106 billion), but results in the most recent quarter still edged analyst ... [Published IOL - Jul 29 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Pfizer Inc. (PFE) Q2 Earnings Preview: A Penny Here a Penny There

Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 29, 2014. The purpose of the call is to provide an update on Pfizer's results, ... [Published I Stock Analyst - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Pfizer Earnings May Miss As Revenues Fall Due To Patent Expiry

Pfizer’s earnings may be below expectations, as revenues decline due to patent expiry of major drugs that caused cheaper generics to flood the marketClick Ticker to See live coveragePfizer ( PFE ) is expected to announce earnings for the second quarter ... [Published Bidness Etc - Jul 28 2014]
Entities: Pfizer Inc, Drugs, Patent
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Vaccine costs soar

There is little that Dr. Lindsay Irvin has not done for the children's vaccines in her office refrigerator: She remortgaged her home to afford their rising prices. She packed them in ice chests and moved them when her office flooded this year. She pays ... [Published Tampa Bay Times - Jul 16 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Human medicines European public assessment report (EPAR): Prevenar, pneumococcal saccharide conjugated vaccine, adsorbed, Revision: 20, Authorised

Entities: Prevnar, Vaccine
First reported Jul 14 2014 - Updated Jul 15 2014 - 2 reports

Prices of vaccines–an uncomfortable discussion

Suddenly, there has been a lot of noise about the price of vaccines. Well, there's always been over-exaggerations and outright misinformation about vaccine prices and profits from the antivaccination gang, and they must be embarrassed by the quality of ... [Published Daily Kos - Jul 15 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 1 reports

Could soaring vaccine prices spark Sovaldi-style payer pushback?

With the expense of vaccine production often higher than the manufacturing costs for pharmaceuticals, vaccines once led losses for their manufacturers. But today, vaccines--like Pfizer's ($PFE) Prevnar 13, which scored more than $4 billion in worldwide ... [Published FierceVaccines - Jul 11 2014]
Entities: Vaccine, Prevnar, Pfizer Inc
First reported Jul 03 2014 - Updated Jul 04 2014 - 3 reports

Vaccine Refusal Myths Drive Up Development Costs, Prices

Since last June, Elisabeth Rosenthal at The New York Times has been putting together a deeply reported  investigative series on healthcare costs in the U.S. called “Paying Till It Hurts.” The primary theme of the series is to identify the key factors ... [Published Forbes.com - Jul 03 2014]
Entities: Vaccine, Prevnar, Immunity
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

Prevnar use in seniors is cost-effective now, CDC says. But will it last?

After meeting to discuss the use of Pfizer's($PFE) Prevnar 13 in adults 65 and older late last week, a CDC advisory committee isn't planning to vote on recommendation of the shot just yet. But when it does, it will have a few things to consider--including ... [Published FierceVaccines - Jun 30 2014]

Quotes

...prepares to become a separate, independent global biopharmaceutical company," Baxter BioScience President Ludwig Hantson said in a statement. "… We are confident that Pfizer, with its recognized global leadership in vaccines, will provide the dedicated, ongoing investments necessary to support and advance the availability of these important vaccines."
(MENAFN) Earnings of Pfizer dropped 79 percent in the second quarter compared to last year, when the world "s second-largest drugmaker booked a business spinoff gain of more than USD10 billion, according to Arab News."
Pfizer chief executive Ian Read said he is pleased with the firm's operating performance to date, and continues to see Pfizer "as well positioned to effectively execute on our strategy to further strengthen each of our businesses on a global basis and deliver value to all of our stakeholders"
"Overall, I am pleased with our second-quarter 2014 financial results despite the continued negative impact from product losses of exclusivity and the termination of certain co-promotion collaborations. We updated our 2014 adjusted revenue guidance to reflect the anticipated negative impact associated with expected multi-source generic competition for Celebrex in the U S beginning in December 2014" CFO Frank D'Amelio said in a statement

More Content

All (87) | News (68) | Reports (0) | Blogs (19) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Booster Shots: Pfizer Acquiring Two Baxter Vacc... [Published Genetic Engineering News - 1 hour ago]
Pfizer finally lands vaccines bulk-up with $635... [Published FierceVaccines - 3 hours ago]
Pfizer Scores Vaccine Expansion with Baxter’s P... [Published The Utah People's Post - 3 hours ago]
Pfizer profit falls 79 percent in Q2 [Published MENAFN - 10 hours ago]
Pfizer leaves investors guessing on intentions ... [Published Yahoo! Malaysia - 23 hours ago]
UPDATE 3-Pfizer leaves investors guessing on in... [Published Reuters UK - 23 hours ago]
Pfizer Inc (NYSE:PFE) | Pfizer Announces Positi... [Published Jutia Group - Jul 29 2014]
Earnings at Pfizer tank but still just beat exp... [Published Pharma Letter - Jul 29 2014]
Pfizer Inc. Beats Q2 Estimates; Narrows FY Outl... [Published Dividend.com - Jul 29 2014]
Pfizer's profit sinks [Published IOL - Jul 29 2014]
BREAKING NEWS: Pfizer's sales, income drop for Q2 [Published Pharma Times - Jul 29 2014]
Pfizer Beats on Q2 Earnings, Revs Despite Gener... [Published Zacks.com - Jul 29 2014]
Pfizer revenue drops, but new cancer drugs shine [Published Pharmafocus - Jul 29 2014]
Pfizer beats estimates as Viagra loses patent p... [Published Fortune - Jul 29 2014]
Pfizer Beats Forecasts Despite Slumping Sales [Published RTTNews.com - Jul 29 2014]
Drugmaker Pfizer's 2nd quarter profit sinks 79 ... [Published Newstalk 1290 CJBK - Jul 29 2014]
Pfizer Inc. (PFE) Q2 Earnings Preview: A Penny ... [Published I Stock Analyst - Jul 28 2014]
Pfizer, Merck, Amgen Near Q2 Earnings Reports [Published Investor's Business Daily - Jul 28 2014]
Pfizer Earnings May Miss As Revenues Fall Due T... [Published Bidness Etc - Jul 28 2014]
Pfizer's Incoming Patent Cliff [Published Motley Fool - Jul 24 2014]
Berko: An investor Rx for Pfizer [Published Des Moines Business Record - Jul 24 2014]
Roundtable: 3 Stocks Janet Yellen Is Dead Wrong... [Published Motley Fool Discussion Boards - Jul 19 2014]
Business Solutions Director, Business Analytics... [Published PharmaDiversity - Jul 18 2014]
Poverty, poor health, exposure are risk factors... [Published Orthopedics Today - Jul 16 2014]
Vaccine costs soar [Published Tampa Bay Times - Jul 16 2014]
Forum Post: RE: Vaccines and CLL [Published Macmillan Cancer Support - Jul 16 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jul 15 2014]
Prices of vaccines–an uncomfortable discussion [Published Daily Kos - Jul 15 2014]
Vanishing vaccinations [Published Register-Guard - Jul 14 2014]
Berko: Patience with drug firm Pfizer may event... [Published Columbian.com - Jul 13 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jul 15 2014]
Valeant's Misleading Case [Published In the Pipeline - Jun 12 2014]
Matthew Herper has excellent coverage here of Valeant's bid for Allergan, specifically Valeant's view of actual pharma R&D (which they, for the most part, don't bother to do). He's especially peeved (with reason) that the company is citing some of ...
Adult and Adolescent Vaccines Market to 2018 - ... [Published PR Newswire: Health - Jun 09 2014]
NEW YORK, June 9, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval ...
A Look at Pfizer’s Recent Financial Performance [Published Wall St. Cheat Sheet - May 15 2014]
Pfizer ( NYSE:PFE ) is getting a lot of attention lately, mostly given its potential deal with AstraZeneca ( NYSE:AZN ). This topic has been thoroughly covered lately. But despite the drama surrounding the headlines of late, Pfizer is still my ...
Where Will Pfizer Go Next? [Published Wall St. Cheat Sheet - May 06 2014]
With shares of Pfizer ( NYSE:PFE ) trading around $29, is PFE an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework : T = Trends for a Stock’s Movement Pfizer is a biopharmaceutical ...
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.